Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Unum Therapeutics Inc (UMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8122
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Unum Therapeutics Inc (Unum Therapeutics) is a clinical-stage bio-pharmaceutical company focused on the development and commercialization of novel antibody-coupled cellular immunotherapies to fight cancers. Its pipeline product portfolio include ACTR087 + rituximab, a CD20 targeting chimeric monoclonal antibody to treat non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia; ACTR707 + rituximab as well as ACTR707 + Trastuzumab for the treatment of HER2+ cancers; ACTR087 + SEA-BCMA against multiple myeloma. The company uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology in combination of tumor-targeting antibodies which direct individual cytotoxic T-lymphocytes (CTLs) to activate the body’s own immune system to fight hematologic and solid tumor cancers. The company seeks to works in partnership with other biotechnology companies to develop new combinations of ACTR T-cells and tumor targeting antibodies. Unum Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Unum Therapeutics Inc (UMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Unum Therapeutics Raises USD65 Million in Series B Financing 11
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 13
Licensing Agreements 14
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 14
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 15
Equity Offering 17
Unum Therapeutics Raises USD69.2 Million in IPO 17
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 19
Unum Therapeutics Inc – Key Competitors 20
Unum Therapeutics Inc – Key Employees 21
Unum Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 13, 2018: Unum Therapeutics reports second quarter 2018 financial results and provides business update 23
May 14, 2018: Unum Therapeutics Announces First Quarter 2018 Financial Results 25
Research And Development 27
Apr 03, 2017: Unum Therapeutics to present new data on ACTR platform at AACR 2017 27
Corporate Communications 28
Mar 02, 2018: Unum Therapeutics Appoints Karen J. Ferrante And Robert J. Perez As Board Directors 28
Mar 02, 2018: Unum Therapeutics Announces Names Christiana Stamoulis To Additional Role Of President 29
Product News 30
10/27/2017: Unum Therapeutics to Present New Data on its Antibody-Coupled T Cell Receptor Platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 30
05/09/2017: Unum Therapeutics to Present Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming Annual Meeting of the American Society of Gene & Cell Therapy 31
Product Approvals 32
Aug 23, 2017: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma 32
Clinical Trials 33
Jul 12, 2018: Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematological Diseases 33
Nov 01, 2017: Unum Therapeutics Announces Presentation of Initial Clinical Data from the ATTCK-20-2 Trial and Pre-Clinical Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming 59th American Society of Hematology (ASH) Annual Meeting 34
Jun 19, 2017: Unum Therapeutics Announces Active Investigational New Drug Application for ACTR707 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Lymphoma 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Unum Therapeutics Raises USD65 Million in Series B Financing 11
Unum Therapeutics Raises USD12 Million in Series A Venture Financing 13
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 14
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 15
Unum Therapeutics Raises USD69.2 Million in IPO 17
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 19
Unum Therapeutics Inc, Key Competitors 20
Unum Therapeutics Inc, Key Employees 21

List of Figures
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Unum Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Unum Therapeutics Inc (UMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FLSmidth & Co AS (FLS):企業の財務・戦略的SWOT分析
    FLSmidth & Co AS (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Xencor Inc (XNCR):企業の財務・戦略的SWOT分析
    Summary Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The company provides pipeline products under preclinical development such as XmAb14045, for the …
  • F5 Networks, Inc.:企業の戦略・SWOT・財務情報
    F5 Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary F5 Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • State Bank Of India
    State Bank Of India - Strategy, SWOT and Corporate Finance Report Summary State Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Cencosud SA:戦略・SWOT・企業財務分析
    Cencosud SA - Strategy, SWOT and Corporate Finance Report Summary Cencosud SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • OTE Group:企業の戦略・SWOT・財務分析
    OTE Group - Strategy, SWOT and Corporate Finance Report Summary OTE Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • TALi Digital Ltd (NHL):企業の財務・戦略的SWOT分析
    TALi Digital Ltd (NHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Exonate Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Exonate Ltd (Exonate) is a biopharmaceutical company that discovers and develops small molecule drugs, which modulates the alternative mRNA splicing for the treatment of unmet medical needs. The company’s alternative mRNA splicing is modulated in disease states that results in the pathologic …
  • Sociedad General de Aguas de Barcelona SA:企業の戦略的SWOT分析
    Sociedad General de Aguas de Barcelona SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • CivaTech Oncology Inc:医療機器:M&Aディール及び事業提携情報
    Summary CivaTech Oncology Inc (CivaTech) is a medical device company that provides radiation therapy solutions. The company develops polymer based low dose rate (LDR) brachytherapy devices for the treatment of cancer. Its product portfolio includes CivaString, a radiation therapy device to treat sol …
  • NextEra Energy Inc (NEE)-エネルギー分野:企業M&A・提携分析
    Summary NextEra Energy, Inc. (NEE), formerly FPL Group, Inc., is an energy company that generates, transmits and distributes electricity together with its subsidiaries. The company generates power through various sources such as nuclear, coal, oil and natural gas-fired facilities, and hydro power pl …
  • TransMontaigne Product Services LLC:企業の戦略・SWOT・財務情報
    TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report Summary TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Sharp Corporation:企業の戦略・SWOT・財務分析
    Sharp Corporation - Strategy, SWOT and Corporate Finance Report Summary Sharp Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Groupe PSA:企業の戦略・SWOT・財務分析
    Groupe PSA - Strategy, SWOT and Corporate Finance Report Summary Groupe PSA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Finastra Group Holdings Limited:企業の戦略・SWOT・財務情報
    Finastra Group Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Finastra Group Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Medical & Biological Laboratories Co Ltd (4557)-医療機器分野:企業M&A・提携分析
    Summary Medical & Biological Laboratories Co Ltd (MBL) is a provider of clinical and basic laboratory diagnostics. The company’s products comprise research reagents, diagnostic reagents and companion diagnostics. It provides diagnostic reagents for therapeutic areas of allergy, antiphospholipid synd …
  • Strides Shasun Limited:企業のM&A・事業提携・投資動向
    Strides Shasun Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Strides Shasun Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Halma Plc (HLMA):企業の財務・戦略的SWOT分析
    Halma Plc (HLMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Syngenta AG:企業の戦略・SWOT・財務分析
    Syngenta AG - Strategy, SWOT and Corporate Finance Report Summary Syngenta AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • International Coffee & Tea, LLC:企業の戦略・SWOT・財務情報
    International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report Summary International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆